These signaling pathways are closely associated with the progression of SCLC (Masumoto et al., 2023; Xu et al., 2024; Zha et al., 2021), providing a strong theoretical basis for considering PAK6 as a tumor marker. The gene discussed is PAK6; the disease is neoplasm.